A new study shows that while RSV mostly affects younger kids, the often-overlooked human metapneumovirus also hospitalizes ...

US Government cuts to mRNA vaccine research could set technological advances, reduce access and raise costs for new therapies ...

This monoclonal antibody from AstraZeneca/Sanofi could be crucial to protect babies born long before the RSV season, making the potential maternal vaccine less useful.

Weekly hospital admission rates for RSV have doubled over the past month among children. In the week ending November 18, there were about 23 hospitalizations for every 100,000 children under 5.

FDA approves Merck's RSV shot for infants, ramping up competition with Sanofi and AstraZeneca By Annika Kim Constantino, CNBC • Published June 9, 2025 • Updated on June 9, 2025 at 3:15 pm ...

In a news release, AstraZeneca said it expects the FDA to grant its drug nirsevimab in the third quarter of 2023, which would place it right before the 2023-24 RSV season usually hits. The drug is ...

Sanofi boosts Beyfortus output for RSV season while Dupixent trial shows strong eczema relief in patients with skin of color.

Weekly hospital admission rates for RSV have doubled over the past month among children. In the week ending November 18, there were about 23 hospitalizations for every 100,000 children under 5.

Merck's shot will compete against a similar blockbuster treatment from Sanofi and AstraZeneca called Beyfortus, which was in short supply nationwide during the 2023 RSV season due to unprecedented ...